Prokaryotic expression and preparation of polyantibody of human histydyl-tRNA synthetase related gene

Abstract

The aim of this study was to express and purify human histydyl-tRNA synthetase related gene and to prepare its polyantibody. The open reading frame was amplified by PCR, and then recombined into prokaryotic expression vector pQE30 and transformed into E. coli M15 for expression. The expressed products were induced by IPTG after the reconstructed pQE30 was transferred into M15. After purified by Ni affinity chromatography, the product was identified to be a single band by SDS-PAGE. The rabbits were inoculated with purified products. High-titer polyantibody was successfully prepared. Highly-purified expression product and prepared polyantibody may provide a good basis for further study.

Keywords

human histydyl-tRNA synthetase related gene / polyantibody / purification

References

[1] MengX F, ChenJ Z, YangQ, et al. . Cloning and expression a full length cDNA of the human histydyl-tR NA synthetase related gene. Fudan Xue Bao (Nat Sci), 2002, 11(1): 75-75

[2] MengX, ChenJ, YangQ, et al. . Cloning and identifieation of a novel cDNA which may be associated with FK BP25. Biochem Genet, 2002, 40(9–10): 303-303

[3] JanknechtR, de MartynoffG, LouJ, et al. . Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. Proc Natl Acad Sci USA, 1991, 88(20): 8972-8972

[4] StacieJ, Froelich-Ammon, NedO. Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism. J Biol Chem, 1995, 270(37): 21129-21129

[5] IshidaR, IwaiM, MarshK L, et al. . Throconine 1342 in Human Topoisomerase II is Phosphorylated Throughout the Cell Cycle. J Biol Chem, 1996, 271(50): 30077-30077

[6] PalmerI, WingfieldP T. Preparation and extraction of insoluble (inclusion-body) proteins fromEsdherichia coli, Current protocals in protein science, 1995, New York, John Wiley & Sons, Inc.: 6-6

[7] PommierY. DNA topoisomerase I and II in cancer chemotherapy: upate and perspectives. Cancer Chemother Pharmacol, 1993, 32(2): 103-103